Catalent Pharma Solutions, is investing more than $27 million to commercialize its next-generation oral disintegrating tablet (ODT) technology, Zydis Ultra. The technology allows an increased drug load and taste masking to be incorporated into the company’s Zydis ODT dosage form, which is a freeze-dried tablet that disperses almost instantly in the mouth without water.   Zydis Ultra allows an innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active...